Want to see PIII full AI Analyst Report?
PIII Stock Chart & Stats
$9.22
$0.86(8.94%)
At close: 4:00 PM EDT
$9.22
$0.86(8.94%)
Day’s Range― - ―
52-Week Range$1.52 - $16.89
Previous Close$10.48
Volume34.66K
Average Volume (3M)14.54K
Market Cap
$29.24M
Enterprise Value$374.70M
Total Cash (Recent Filing)$21.27M
Total Debt (Recent Filing)$130.27M
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 18, 2026EPS Estimate
-3.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.95
Shares Outstanding4,015,604
10 Day Avg. Volume17,552
30 Day Avg. Volume14,538
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.07
Price to Sales (P/S)0.00782
P/FCF Ratio-0.13
Enterprise Value/Market Cap12.82
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.79
Enterprise Value/Ebitda-4.55
Forecast
1Y Price Target
$18.00Price Target Upside95.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-12.08
Revenue Forecast (FY)$1.55B
Bulls Say, Bears Say
Bulls Say
Revenue And Per-Member Funding GrowthHigher revenue and per-member funding indicate improved economics within the value-based care model, even with a smaller at-risk population. If sustained, stronger funding per member can support care investments, offset utilization pressure, and improve operating leverage over coming quarters.
Underlying EBITDA ImprovementPositive underlying EBITDA suggests the core operating model is moving beyond dependence on reported losses and toward self-funded operations. This improvement can strengthen management’s ability to invest in clinical programs, technology, and market expansion while reducing reliance on external capital.
Improving Medical Cost PerformanceA medical cost trend below the prior-year baseline supports the economics of P3’s population-health model because savings can improve results under value-based contracts. Continued control of utilization and care costs would make margins more resilient across future reporting periods.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow means accounting improvement has not yet translated into internally generated liquidity. Continued cash consumption can constrain investment, increase dependence on financing, and leave the company less flexible if operating gains take longer to mature.
Nonrecurring Support To Reported EBITDAA substantial portion of reported EBITDA came from settlements and prior-period development rather than recurring current-period operations. This reduces the quality and predictability of headline profitability, leaving future results more dependent on sustained clinical and administrative execution.
Expensive Preferred FinancingThe financing improves near-term liquidity but carries a high cumulative dividend and ranks ahead of common equity, increasing the cost of capital. These terms can absorb future cash resources and limit shareholder value creation unless operating cash generation improves materially.
P3 Health Partners News
PIII FAQ
What was P3 Health Partners’s price range in the past 12 months?
P3 Health Partners lowest stock price was $1.52 and its highest was $16.89 in the past 12 months.
What is P3 Health Partners’s market cap?
P3 Health Partners’s market cap is $29.24M.
When is P3 Health Partners’s upcoming earnings report date?
P3 Health Partners’s upcoming earnings report date is Nov 18, 2026 which is in 27 days.
How were P3 Health Partners’s earnings last quarter?
P3 Health Partners released its earnings results on Aug 10, 2026. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$1.895 by $1.265.
Is P3 Health Partners overvalued?
According to Wall Street analysts P3 Health Partners’s price is currently Undervalued.
Does P3 Health Partners pay dividends?
P3 Health Partners does not currently pay dividends.
What is P3 Health Partners’s EPS estimate?
P3 Health Partners’s EPS estimate is -3.97.
How many shares outstanding does P3 Health Partners have?
P3 Health Partners has 4,015,604 shares outstanding.
What happened to P3 Health Partners’s price movement after its last earnings report?
P3 Health Partners reported an EPS of -$0.63 in its last earnings report, beating expectations of -$1.895. Following the earnings report the stock price went down -3.585%.
Which hedge fund is a major shareholder of P3 Health Partners?
Currently, no hedge funds are holding shares in PIII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
PIII Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational progress: revenue growth, improved per-member funding (+15% YoY), positive underlying adjusted EBITDA (≈$9M Q2, ≈$18M H1), a lowered MA medical cost trend (‑1.8% vs. 2025) and upgraded full-year guidance to $80M–$110M. However, a sizable portion of reported profitability in H1 (≈$62M) came from favorable payer settlements and prior-period development, introducing nonrecurring support to headline results. Management emphasizes that the core business is now generating positive EBITDA and is executing on clinical, technology and contractual initiatives to sustain performance, but back-half seasonality, membership concentration and a modest cash balance are risks to monitor. Overall, the positives and momentum outweigh the cautions, though sustainability will depend on continued execution and fewer one-time contributions.View all PIII earnings summariesPIII Stock 12 Month Forecast
Average Price Target
$18.00
▲(95.23% Upside)
Technical Analysis
Ownership Overview
18.17% Insiders
11.86% Mutual Funds
1.64% Other Institutional Investors
67.30% Public Companies and
Individual Investors